Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 13/20 | 1.00 |
| ▸ | P2RX1 | P51575 | 15/20 | 0.74 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.71 |
| ▸ | P2RX4 | Q99571 | 6/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | IKBKB | O14920 | 1/20 | 0.71 |
| ▸ | CHUK | O15111 | 1/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.71 |
| ▸ | FLT3 | P36888 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | MYLK | Q15746 | 1/20 | 0.71 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.71 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129638 | 0.94 | TMPRSS4 (0.90) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL16707253 | 0.94 | TMPRSS4 (0.88) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL30771749 | 0.89 | TMPRSS4 (0.80) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL17845892 | 0.89 | TMPRSS4 (0.80) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL330388 | 0.88 | TMPRSS4 (0.78) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL134080 | 0.88 | TMPRSS4 (0.77) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL130439 | 0.87 | P2RX1 (0.81) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL330392 | 0.86 | TMPRSS4 (0.75) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL23303456 | 0.85 | P2RX1 (1.00) | TMPRSS4P2RX1P2RX7P2RX4MEN1 | |
| SCHEMBL132386 | 0.84 | P2RX1 (1.00) | TMPRSS4P2RX1P2RX7P2RX4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2014-08-07 | — | — | US | claimed |
| EP-1352650-B1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | INST MED MOLECULAR DESIGN INC (JP) | 2012-03-07 | — | — | EP | claimed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | claimed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | claimed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | claimed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | claimed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | claimed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | claimed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | claimed |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2021086567-A1 | COMPOUNDS AND METHODS FOR POTENTIATING COLISTIN ACTIVITY | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20180042873-A1 | NOVEL METHODS | AEROMICS, INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-9573885-B2 | Methods of treating cerebral edema | AEROMICS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20160346302-A1 | NOVEL METHODS | AEROMICS, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180042873-A1 | NOVEL METHODS | AQP4, AQP1, AQP3 | TMPRSS4 2568/4885P2RX1 2332/4885P2RX7 2547/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | TMPRSS4 4322/4885P2RX1 2484/4885P2RX7 2360/4885 |
| US-20160346302-A1 | NOVEL METHODS | AQP4, AQP1, AQP3 | TMPRSS4 2227/4885P2RX1 400/4885P2RX7 552/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | TMPRSS4 4304/4885P2RX1 2927/4885P2RX7 2720/4885 |
| US-20060094718-A1 | 2-Morpholinocarbonyloxy-),5-(phenylethenyl,N-((3,5-bistrifluoromethyl-)phenyl)-benzamide; inhibitors of nuclear factor kappa B activation; cytokine suppressive antiinflammatory drugs(interleukin (IL-1, IL-6, IL-8) inhibitors); tumor necrosis factor (TNF-alpha) inhibitors; side effects reduction | IL1A, TNF, NFKBIA | TMPRSS4 4278/4885P2RX1 2507/4885P2RX7 2251/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TMPRSS4 1647/4885P2RX1 1538/4885P2RX7 973/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TMPRSS4 1647/4885P2RX1 1538/4885P2RX7 973/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | TMPRSS4 4402/4885P2RX1 2425/4885P2RX7 2267/4885 |
| US-20140221411-A1 | 2-HYDROXYARYLAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING SAME AS ACTIVE INGREDIENT | TMPRSS2, TMPRSS4, PRSS2 | TMPRSS4 2/4885P2RX1 4273/4885P2RX7 4289/4885 |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AQP4, AQP1, AQP3 | TMPRSS4 1444/4885P2RX1 3317/4885P2RX7 3316/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | TMPRSS4 3292/4885P2RX1 2316/4885P2RX7 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.